Back to search

Article

High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRC

2025-07-02

Abstract excerpt

Colorectal cancer (CRC) remains a significant clinical challenge, with a 5-year survival rate of 10%. Over half of all CRCs harbor mutations in the KRAS gene, leading to poor response to standard therapy. This underscores the crucial need for novel therapeutics targeting KRAS and overcoming the growing barrier of resistance. To address these critical challenges, we conducted a high-throughput screen to identify sm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0bb54ef4-7be3-5ef3-b575-e78e30cd4008
DOI
10.1101/2025.06.27.662039
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS <sup>G12D</sup> Mutated CRCDOI 10.1101/2025.06.27.662039
Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12D Inhibitor, in Colorectal Cancer Treatment.Semantic proximity
Efficacy of dual KRASG12D-EGFR blockade versus triple combinations in patient-derived models of KRASG12D-mutant colorectal cancer.Semantic proximity
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.Semantic proximity
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.Semantic proximity
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.Semantic proximity
Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors.Semantic proximity
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity
Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity
VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activationSemantic proximity
Computational repurposing of approved drugs targeting KRAS G12D and EGFR for colorectal cancer therapy.Semantic proximity
The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis.Semantic proximity
Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Semantic proximity
Select a neighboring publication to make it the new centre.